Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 5
2022 8
2023 9
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection.
Xu D, Jiang W, Wu L, Gaudet RG, Park ES, Su M, Cheppali SK, Cheemarla NR, Kumar P, Uchil PD, Grover JR, Foxman EF, Brown CM, Stansfeld PJ, Bewersdorf J, Mothes W, Karatekin E, Wilen CB, MacMicking JD. Xu D, et al. Nature. 2023 Jul;619(7971):819-827. doi: 10.1038/s41586-023-06322-y. Epub 2023 Jul 12. Nature. 2023. PMID: 37438530 Free PMC article.
Structure and inhibition of SARS-CoV-2 spike refolding in membranes.
Grunst MW, Qin Z, Dodero-Rojas E, Ding S, Prévost J, Chen Y, Hu Y, Pazgier M, Wu S, Xie X, Finzi A, Onuchic JN, Whitford PC, Mothes W, Li W. Grunst MW, et al. Science. 2024 Aug 16;385(6710):757-765. doi: 10.1126/science.adn5658. Epub 2024 Aug 15. Science. 2024. PMID: 39146425
Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine.
Grandi A, Tomasi M, Ullah I, Bertelli C, Vanzo T, Accordini S, Gagliardi A, Zanella I, Benedet M, Corbellari R, Di Lascio G, Tamburini S, Caproni E, Croia L, Ravà M, Fumagalli V, Di Lucia P, Marotta D, Sala E, Iannacone M, Kumar P, Mothes W, Uchil PD, Cherepanov P, Bolognesi M, Pizzato M, Grandi G. Grandi A, et al. Vaccines (Basel). 2023 Sep 29;11(10):1546. doi: 10.3390/vaccines11101546. Vaccines (Basel). 2023. PMID: 37896949 Free PMC article.
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy.
Ullah I, Prévost J, Ladinsky MS, Stone H, Lu M, Anand SP, Beaudoin-Bussières G, Symmes K, Benlarbi M, Ding S, Gasser R, Fink C, Chen Y, Tauzin A, Goyette G, Bourassa C, Medjahed H, Mack M, Chung K, Wilen CB, Dekaban GA, Dikeakos JD, Bruce EA, Kaufmann DE, Stamatatos L, McGuire AT, Richard J, Pazgier M, Bjorkman PJ, Mothes W, Finzi A, Kumar P, Uchil PD. Ullah I, et al. Immunity. 2021 Sep 14;54(9):2143-2158.e15. doi: 10.1016/j.immuni.2021.08.015. Epub 2021 Aug 18. Immunity. 2021. PMID: 34453881 Free PMC article.
Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern.
Li W, Chen Y, Prévost J, Ullah I, Lu M, Gong SY, Tauzin A, Gasser R, Vézina D, Anand SP, Goyette G, Chaterjee D, Ding S, Tolbert WD, Grunst MW, Bo Y, Zhang S, Richard J, Zhou F, Huang RK, Esser L, Zeher A, Côté M, Kumar P, Sodroski J, Xia D, Uchil PD, Pazgier M, Finzi A, Mothes W. Li W, et al. Cell Rep. 2022 Jan 11;38(2):110210. doi: 10.1016/j.celrep.2021.110210. Epub 2021 Dec 15. Cell Rep. 2022. PMID: 34971573 Free PMC article.
Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern.
Li W, Chen Y, Prévost J, Ullah I, Lu M, Gong SY, Tauzin A, Gasser R, Vézina D, Anand SP, Goyette G, Chaterjee D, Ding S, Tolbert WD, Grunst MW, Bo Y, Zhang S, Richard J, Zhou F, Huang RK, Esser L, Zeher A, Côté M, Kumar P, Sodroski J, Xia D, Uchil PD, Pazgier M, Finzi A, Mothes W. Li W, et al. bioRxiv [Preprint]. 2021 Aug 3:2021.08.02.454546. doi: 10.1101/2021.08.02.454546. bioRxiv. 2021. Update in: Cell Rep. 2022 Jan 11;38(2):110210. doi: 10.1016/j.celrep.2021.110210. PMID: 34373853 Free PMC article. Updated. Preprint.
Combinatorial Regimens Augment Drug Monotherapy for SARS-CoV-2 Clearance in Mice.
Ullah I, Escudie F, Scandale I, Gilani Z, Gendron-Lepage G, Gaudette F, Mowbray C, Fraisse L, Bazin R, Finzi A, Mothes W, Kumar P, Chatelain E, Uchil PD. Ullah I, et al. bioRxiv [Preprint]. 2023 Jun 1:2023.05.31.543159. doi: 10.1101/2023.05.31.543159. bioRxiv. 2023. Update in: iScience. 2024 Jan 30;27(3):109049. doi: 10.1016/j.isci.2024.109049. PMID: 37398307 Free PMC article. Updated. Preprint.
Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine.
Grandi A, Tomasi M, Ullah I, Bertelli C, Vanzo T, Accordini S, Gagliardi A, Zanella I, Benedet M, Corbellari R, Lascio GD, Tamburini S, Caproni E, Croia L, Ravà M, Fumagalli V, Lucia PD, Marotta D, Sala E, Iannacone M, Kumar P, Mothes W, Uchil PD, Cherepanov P, Bolognesi M, Pizzato M, Grandi G. Grandi A, et al. Res Sq [Preprint]. 2023 May 25:rs.3.rs-2788726. doi: 10.21203/rs.3.rs-2788726/v1. Res Sq. 2023. Update in: Vaccines (Basel). 2023 Sep 29;11(10):1546. doi: 10.3390/vaccines11101546. PMID: 37292970 Free PMC article. Updated. Preprint.
Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD.
Chen Y, Prévost J, Ullah I, Romero H, Lisi V, Tolbert WD, Grover JR, Ding S, Gong SY, Beaudoin-Bussières G, Gasser R, Benlarbi M, Vézina D, Anand SP, Chatterjee D, Goyette G, Grunst MW, Yang Z, Bo Y, Zhou F, Béland K, Bai X, Zeher AR, Huang RK, Nguyen DN, Sherburn R, Wu D, Piszczek G, Paré B, Matthies D, Xia D, Richard J, Kumar P, Mothes W, Côté M, Uchil PD, Lavallée VP, Smith MA, Pazgier M, Haddad E, Finzi A. Chen Y, et al. iScience. 2023 Jan 20;26(1):105783. doi: 10.1016/j.isci.2022.105783. Epub 2022 Dec 9. iScience. 2023. PMID: 36514310 Free PMC article.
22 results